-
About Us
About Us
The word “Amicogen” consists of the meaning of friend, “AMICO”
in Latin and of gene, “GENE”. We developed innovative biocatalysts
and proteins by applying our proprietary i DNA Evolution™ Technology.
We are a “Bioengineering company just like a Sincere Friend”
who contributes to the human health and the preservation of environment.
Amicogen is the representative Industrial Biotechnology Company in Korea
and wants to contribute to the protection of human health and the environment. -
R&D
R&D
Amicogen Biotech R&D Center is expanding its R&D field based on
bio-platform technology, and researchers account for 30% of all employees.
We will lead the Industrial Biotechnology to develop new technologies
that can drive the development of humanity and society,
one step further than others.
Amicogen continues innovative research
and development for its first and best products. -
Products
Products
Amicogen has developed Special Enzymes for industrial and pharmaceutical products based on the i DNA evolution™.
We want to contribute to the sustainable growth and lifelong health
of humanity by developing New Bio-Ingredientfor Health functional foods
with Special Enzymes and Protein Purification Resin.
Amicogen develops Bio Products and
New Bio-Ingredients for Health functional food. -
Investors
Investors
As Amicogen started as a bio-venture company, we have focused on
the core competence of R&D and are pursuing sustainable growth
in innovative technologies and products. To increase the value
of enterprise and shareholder, we are continually strengthening our core competencies such as specialty enzyme business, healthcare, protein
purification resin business and others.
Amicogen strengthens key capacities
to increase enterprise value and shareholder value. -
Media
Media
Amicogen promotes various activities to realize the value of contributing
to the protection of human health and the environment.
Amicogen is positioning itself as a global biotechnology company
through growth and leaps to create new values.
You can find various looks and news of Amicogen
taking the initiative in the global bio industry. -
ESG
Sustainable management
Amicogen has developed bio innovative technologies and operated the businesses that consider humankind and environment from the perspective of sustainability for the past 20 years. We will continue sustainable development based on Amicogen's environmental soundness, social responsibility and sustainable innovative technology.
Amicogen wants to contribute to the protection of human health and the environment. -
Careers
Careers
Amicogen produces new technologies and values based on
creative thinking and constant technological innovation through human
oriented management. We do our best to ensure that talented individuals
with unique skills and abilities can demonstrate their abilities
according to the nature of their duties.
We are waiting for Amicogen people,
who will open new values and a bright future. -
CONTACT
Careers
Amicogen produces new technologies and values based on
creative thinking and constant technological innovation through human
oriented management. We do our best to ensure that talented individuals
with unique skills and abilities can demonstrate their abilities
according to the nature of their duties.We are waiting for Amicogen people,
who will open new values and a bright future.
IR Letter
Amicogen IR Letter
Amicogen will try our best to maximize our shareholders' value
and realize the full potential of the company.
| No. | Classify | Title | Date |
|---|---|---|---|
| 42 | IR Letter | 2020년 1분기 IR Letter | 2020-05-20 |
| 41 | IR Letter | 제 20기 정기주주총회 소집 공고 | 2020-03-13 |
| 40 | Notice | 외부감사인 선임 공고 | 2024-02-02 |
| 39 | IR Letter | 2019 3분기 IR Letter | 2019-11-24 |
| 38 | IR Letter | 2019년 2분기 IR Letter | 2018-08-16 |
| 37 | IR Letter | 2019년 1분기 IR Letter | 2019-05-16 |
| 36 | IR Letter |
 제19기 결산공고
|
2019-03-30 |
| 35 | IR Letter |
제19기 정기주주총회 소집공고 정정
|
2019-03-15 |
| 34 | IR Letter |
2018년 3분기 실적발표 프리젠테이션(국문)
|
2018-11-26 |
| 33 | IR Letter | 2018년 2분기 IR Letter | 2018-08-23 |